Don't let it sit on a receiving dock or a lab bench
This point is effectively made in a recently conducted large trial, which states that, our understanding of the mechanisms of cardiovascular protection with [the GLP-1 agonist] semaglutide remains speculativeclinical benefit is [thought to be] achieved through multiple interrelated pathways. Acknowledgement of this evidence gap prompted our lab, through use of a large animal model of CAD that replicates the features of disease as it occurs in humans, to investigate the cardiac consequences of semaglutide administration
Furthermore, Foundayo (orforglipron) grants patients an innovative oral GLP-1 option consumed without mealtime restrictions
Davies M, et al
In the years before biosimilar entry, AbbVie invested aggressively in building out its immunology pipeline acquiring Allergan for $63 billion in 2020, a transaction that added Botox, Juvederm, and a range of non-Humira products to the portfolio [30]
Traditional approaches like calorie restriction, exercise plans, or over-the-counter supplements continue to attract attention, but their results are inconsistent and often short-lived